Arrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to develop ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Analyst Kostas Biliouris of BMO Capital reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals said they have entered a licensing and collaboration agreement worth more than $1 billion.

Arrowhead Pharmaceuticals (ARWR) stock surges 21% in premarket after $825M licensing deal with Sarepta (SRPT) for rare ...

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

马萨诸塞州剑桥 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT)与Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)签订了一项全球许可协议,获得了一系列针对肌肉、中枢神经系统 ...

Sarepta Therapeutics今日宣布与Arrowhead ...

Shares of Arrowhead Pharmaceuticals ($ARWR) surged as much as 22% in pre-market trading on Tuesday after announcing a $825 ...